Search results
Added:
1 year ago
Added:
4 days ago
Source:
Radcliffe CVRM
Recent US guidelines have controversially recommended lowering the low-density lipoprotein cholesterol (LDL-C) target to <55 mg/dL for patients with established atherosclerotic cardiovascular disease (ASCVD).¹˒² The Ez-PAVE trial is the first randomised study to directly compare this intensive target with a conventional target of <70 mg/dL. The findings were published in The New England…
View more
Added:
3 weeks ago
Source:
Radcliffe CVRM
Individuals with type 2 diabetes (T2D) face a high risk of atherosclerotic cardiovascular disease (ASCVD). The SOUL trial (NCT03914326) previously demonstrated that oral semaglutide reduced major adverse cardiovascular events (MACE).² A new post hoc secondary analysis of this trial now provides insight into the mechanisms behind this benefit, detailing the drug's association with changes in key…
View more
Added:
3 months ago
Source:
Radcliffe CVRM
Radcliffe Cardiology has announced New Horizons in Dyslipidaemia 2026, a live virtual event on 12 February 2026 (14:00–17:55 GMT) that will convene twelve international leaders to examine how lipid management is evolving, and where current practice continues to fall short.Despite the availability of highly effective lipid-lowering therapies, residual cardiovascular risk remains common. At the…
View more
Added:
7 months ago
ESC Congress 2025 - Pooled MACE Analysis of obicetrapib shows reductions in cardiovascular events and consistent reductions in LDL cholesterol and LP(a).Prof Stephen Nicholls (Monash Victorian Heart Institute, AU) joins us to discuss findings from a pooled major adverse cardiovascular events (MACE) analysis of obicetrapib, examining early signals of cardiovascular benefit in patients with…
View more
Added:
1 month ago
Source:
Radcliffe CVRM
For patients with heterozygous familial hypercholesterolemia (HeFH), achieving adequate low-density lipoprotein cholesterol (LDL-C) lowering remains a significant challenge. New results from the BROOKLYN trial suggest that the investigational agent obicetrapib could be an effective add-on therapy for this high-risk population.¹Mechanism of ActionObicetrapib is a highly selective cholesteryl ester…
View more
Added:
6 days ago
Added:
5 days ago
Added:
5 months ago
AHA Scientific Sessions 2025 - Phase 1 results show the CRISPR-Cas9 gene editing therapy is a safe treatment option targeting ANGPTL3 in patients with lipid disorders.Prof Stephen Nicholls (Monash Victorian Heart Institute, Clayton, AU) joins us to share results from a first-in-human phase 1 trial investigating a one-time infusion of CTX310, a CRISPR-Cas9 gene editing therapy, at different doses…
View more
Added:
1 year ago